Lantern Pharma Expands predictBBB Platform into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), enabling real-time molecular intelligence for drug discovery, which could accelerate development and reduce costs.
Lantern Pharma (NASDAQ: LTRN) announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), a real-time, web-based molecular intelligence engine that allows researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern's RADR AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture, and topological mapping, with benchmark-validated performance. This expansion aims to streamline drug discovery workflows and broaden access to advanced computational tools, potentially reducing the time and cost associated with early-stage drug development.
The LQM platform is designed to be accessible to researchers without requiring extensive computational expertise, democratizing the use of AI in drug discovery. By integrating Lantern's proprietary AI and machine learning capabilities, the platform can analyze vast datasets to predict molecular behavior, identify potential candidates, and optimize lead compounds. This could have significant implications for the pharmaceutical industry, where the failure rate of drug candidates in clinical trials remains high, and the average cost of developing a new drug exceeds $1 billion. Tools like the LQM may help researchers prioritize molecules with higher chances of success, thereby improving the efficiency of the drug development pipeline.
Lantern Pharma is a clinical-stage precision oncology company that leverages AI and its proprietary RADR platform to transform cancer therapy development. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. Additionally, Lantern's withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform, representing a new revenue stream for the company.
The expansion of predictBBB into an LQM underscores Lantern's commitment to advancing computational drug discovery. The platform's real-time capabilities and web-based accessibility could enable researchers worldwide to rapidly assess molecular properties, potentially accelerating the identification of drug candidates for a range of diseases. This development aligns with broader industry trends toward integrating AI and machine learning into drug discovery to improve success rates and reduce costs. For more information on Lantern Pharma, visit their newsroom.